FDG PET/CT imaging after just one week may predict treatment response in patients with advanced melanoma
Bottom Line: Imaging the tumours of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than…
Bottom Line: Imaging the tumours of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than…
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall…
Patients with metastatic or recurrent cervical cancer not amenable to curative surgery and/or radiotherapy have…
Considering the molecular subtype of muscle-invasive bladder cancer (MIBC) based on differences in tumour RNA…
Detailed results from CABINET (A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo…
The results from the Phase 3 MARIPOSA-2 study have been announced showing the regimen of…
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy…
The randomised, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib…